Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Autor: Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL

Publikováno v: Journal of Clinical Oncology; 4/10/2009, Vol. 27 Issue 11, p1850-1856, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.

Autor: Cappellini MD; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Taher AT; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Piga A; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Shah F; Department of Haematology, Whittington Health NHS Trust, London, UK., Voskaridou E; Centre of Excellence in Rare Haematological Diseases-Haemoglobinopathies, Laiko General Hospital, Athens, Greece., Viprakasit V; Siriraj Hospital, Mahidol University, Bangkok, Thailand., Porter JB; University College London Hospitals NHS Foundation Trust, London, UK., Hermine O; Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Imagine Institute, INSERM Unité 1163, University of Paris, Paris, France., Neufeld EJ; St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Thompson AA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA., Tang D; Bristol Myers Squibb, Princeton, New Jersey, USA., Yucel A; Bristol Myers Squibb, Princeton, New Jersey, USA., Lord-Bessen J; Bristol Myers Squibb, Princeton, New Jersey, USA., Yu P; Evidera, Waltham, Massachusetts, USA., Guo S; Evidera, Waltham, Massachusetts, USA., Shetty JK; Bristol Myers Squibb, Princeton, New Jersey, USA., Miteva D; Bristol Myers Squibb, Princeton, New Jersey, USA., Zinger T; Bristol Myers Squibb, Princeton, New Jersey, USA., Backstrom JT; Acceleron Pharma Inc., a Subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA., Oliva EN; Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.

Publikováno v: European journal of haematology [Eur J Haematol] 2023 Jul; Vol. 111 (1), pp. 113-124. Date of Electronic Publication: 2023 Apr 24.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

Autor: Taher AT; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: ataher@aub.edu.lb., Cappellini MD; Fondazione IRCCS Ca' Granda Policlinico Hospital, University of Milan, Milan, Italy., Kattamis A; First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece., Voskaridou E; Thalassemia and Sickle Cell Center of Laiko General Hospital, Athens, Greece., Perrotta S; Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università della Campania, Luigi Vanvitelli, Naples, Italy., Piga AG; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Filosa A; Rare Red Blood Cell Disease Unit, Cardarelli Hospital, Naples, Italy., Porter JB; University College London, University College London Hospitals, London, UK., Coates TD; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA; University of Southern California Keck School of Medicine, Los Angeles, CA, USA., Forni GL; Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, Ospedale Galliera, Genoa, Italy., Thompson AA; Ann & Robert H Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Tartaglione I; Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università della Campania, Luigi Vanvitelli, Naples, Italy., Musallam KM; Thalassemia Center, Burjeel Medical City, Abu Dhabi, United Arab Emirates; International Network of Hematology, London, UK., Backstrom JT; Acceleron Pharma, Cambridge, MA, USA., Esposito O; Celgene International Sàrl, Boudry, Switzerland., Giuseppi AC; Bristol Myers Squibb, Princeton, NJ, USA., Kuo WL; Bristol Myers Squibb, Princeton, NJ, USA., Miteva D; Celgene International Sàrl, Boudry, Switzerland., Lord-Bessen J; Bristol Myers Squibb, Princeton, NJ, USA., Yucel A; Bristol Myers Squibb, Princeton, NJ, USA., Zinger T; Celgene International Sàrl, Boudry, Switzerland., Shetty JK; Celgene International Sàrl, Boudry, Switzerland., Viprakasit V; Siriraj Research Hospital, Mahidol University, Bangkok, Thailand.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2022 Oct; Vol. 9 (10), pp. e733-e744. Date of Electronic Publication: 2022 Aug 22.

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.

Autor: Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Mufti GJ; Department of Haemato-Oncology, King's College London, London, United Kingdom., Fenaux P; Service d'Hématologie Séniors, Hôpital Saint Louis, Université Paris 7, Paris, France., Buckstein R; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Santini V; MDS Unit, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Díez-Campelo M; Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain., Finelli C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli' Bologna, Bologna, Italy., Ilhan O; Department of Hematology, Ankara University School of Medicine, Ankara, Turkey., Sekeres MA; Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL., Zeidan AM; Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT., Ito R; Bristol Myers Squibb, Princeton, NJ., Zhang J; Bristol Myers Squibb, Princeton, NJ., Rampersad A; Bristol Myers Squibb, Princeton, NJ., Sinsimer D; Bristol Myers Squibb, Princeton, NJ., Backstrom JT; Acceleron Pharma, Cambridge, MA., Platzbecker U; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; and., Komrokji RS; Moffitt Cancer Center, Tampa, FL.

Publikováno v: Blood [Blood] 2022 Jan 27; Vol. 139 (4), pp. 624-629.